Hosted on MSN11h
Stifel Downgrades IGM Biosciences (IGMS)
Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...
Hosted on MSN11h
Jefferies Downgrades IGM Biosciences (IGMS)
Fintel reports that on January 10, 2025, Jefferies downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to ...
IGM’s autoimmune pivot backfires as top drug disappoints in testing
The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as ...
IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out, sending stock down 69%
IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Average Rating of “Moderate Buy” from Analysts
Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat ...
Geode Capital Management LLC Buys 28,118 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS)
Geode Capital Management LLC raised its stake in shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 7.6% in the third quarter, Holdings Channel reports. The institutional investor owned ...
Endocrinology Advisor2d
Serum CXCL13 Levels Show Potential as a Biomarker for Tailoring Early RA Treatment
High serum CXCL13 levels are predictive of treatment failure with first-line MTX among patients with early RA.